¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2021³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2021-10-01

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2021³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2021-10-01
±³À°ÀÏÀÚ : 2021-10-01
±³À°Àå¼Ò : ¼­¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ ¹× ´ëȸÀǽǠ 
±³À°ÁÖÁ¦ : 2021³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À°
ÁÖÃÖ±â°ü : ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ
´ã´çÀÚ : À̼¼Àº
¿¬¶ôó : 02-784-2742  
À̸ÞÀÏ : secretariat@kcnp.or.kr      
±³À°Á¾·ù : Á¤½Å°Ç°­ÀÇÇаú      
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 4Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 35ºÐ  
¼¼ºÎ¼ö°­·á : 40,000¿ø      
ºñ°í »çÀüµî·Ïºñ Æò»ýȸ¿ø ¸éÁ¦/Á¤È¸¿ø 20,000¿ø/ºñȸ¿ø 30,000¿ø/ÁØȸ¿ø¹×±âŸ 10,000¿ø/´çÀϵî·Ïºñ Æò»ýȸ¿ø 10,000¿ø/Á¤È¸¿ø 30,000¿ø/ºñȸ¿ø 40,000¿ø/ÁØȸ¿ø ¹× ±âŸ 20,000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10-01 ÄÁº¥¼ÇȦ 13:25~13:50 Efficacy of Duloxetine on depression and pain in cancer patients  Á¤Á¾Çö(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 10-01 ´ëȸÀǽǠ13:00~13:50 Reliable long-term management that prevents recurrences and preserves functioning in bipolar disorder  Àå½ÂÈ£(¿ø±¤ÀÇ´ë) 
Åä·Ð 10-01 ÄÁº¥¼ÇȦ 13:50~14:05 Consensus of definition of TRD  ¼ºÇü¸ð/Àå¼¼Çå/¹Ú¿µ¹Î/±è¿ø(¼øõÇâÀÇ´ë/ºÀ»ýº´¿ø/ÀÎÁ¦ÀÇ´ë/ÀÎÁ¦ÀÇ´ë) 
Åä·Ð 10-01 ÄÁº¥¼ÇȦ 14:05~14:20 Pharmacological management for TRD  ¼ºÇü¸ð/Àå¼¼Çå/¹Ú¿µ¹Î/±è¿ø(¼øõÇâÀÇ´ë/ºÀ»ýº´¿ø/ÀÎÁ¦ÀÇ´ë/ÀÎÁ¦ÀÇ´ë) 
Åä·Ð 10-01 ÄÁº¥¼ÇȦ 14:20~14:40 Non-pharmacological management for TRD  ¼ºÇü¸ð/Àå¼¼Çå/¹Ú¿µ¹Î/±è¿ø(¼øõÇâÀÇ´ë/ºÀ»ýº´¿ø/ÀÎÁ¦ÀÇ´ë/ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 10-01 ´ëȸÀǽǠ13:50~14:15 When could Vortioxetine be a relevant treatment option for patients with MDD living through the pandemic?  ÀÌ°­¼ö(Â÷ÀÇ°úÇдë) 
±³À°½Ã°£ 10-01 ´ëȸÀǽǠ14:15~14:40 Dose-response relationship among antidepressant treatment option and for Vortioxetine  ¿Õ¼º¹Î(°¡Å縯ÀÇ´ë) 
È޽Ġ10-01  14:40~14:55   () 
±³À°½Ã°£ 10-01 ÄÁº¥¼ÇȦ 14:55~15:20 Eye-contact game using mixed reality for the treatment of children with attention deficit hyperactivity disorder  ±è±â¹ü(ÇѾç´ë ¿¡¸®Ä« ¼ÒÇÁÆ®¿þ¾î À¶ÇÕ´ëÇÐ) 
±³À°½Ã°£ 10-01 ÄÁº¥¼ÇȦ 15:20~15:45 Virtual school and VR game addiction treatment program for adolescents and young adults  ±èÀºÁÖ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10-01 ÄÁº¥¼ÇȦ 15:45~16:05 Are digital therapeutics appropriate for individuals with ASD?  À¯ÈñÁ¤(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10-01 ´ëȸÀǽǠ14:55~15:20 Homeostasis and allostasis  ÀüÈ«ÁØ(°Ç±¹ÀÇ´ë) 
±³À°½Ã°£ 10-01 ´ëȸÀǽǠ15:20~15:45 Allostasis in addiction  Á¤¿µÃ¶(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10-01 ´ëȸÀǽǠ15:45~16:05 Allostasis in mood disorder  ³ë´ë¿µ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 10-01 ÄÁº¥¼ÇȦ 16:05~16:30 Classic pharmacotherapy for AD and its limitations  ÀÓÇö±¹(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 10-01 ÄÁº¥¼ÇȦ 16:30~16:55 Amyloid-¥â/tau-targeting immunotherapy and its limitations  ¼­½Â¿Ï(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 10-01 ÄÁº¥¼ÇȦ 16:55~17:15 Newly approved drug: Aducanumab  ¾öÀ¯Çö(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 10-01 ´ëȸÀǽǠ16:05~16:30 Pathophysiology in postpartum depression  ÀÓÀº¼º(½Å¼¼°èÈ¿º´¿ø) 
±³À°½Ã°£ 10-01 ´ëȸÀǽǠ16:30~16:55 Prevention and risk factor control for PPD  °­ÇÑ°íÀººñ(±¹¸³³ªÁÖº´¿ø) 
±³À°½Ã°£ 10-01 ´ëȸÀǽǠ16:55~17:15 Allopregnanolone in PPD: Brexanolone  È«Á¤¿Ï(Àͻ꺴¿ø) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2021³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2021-10-01""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2021 ÃæûºÏµµ³»°úÀÇ»çȸ Ãß°èÇмú´ëȸ : 2021-10-02
´ÙÀ½±Û (¿Â¶óÀÎ) ¼Ò¾Æû¼Ò³â°ú ÀÏÂ÷ÀǷῬ±¸È¸ ¿Â¶óÀÎ Áý´ãȸ-¼Ò¾Æ ¾ð¾îÁö¿¬ Æò°¡, ¼Ò¾Æ ¹ß´Þ°ú Çൿ ÀÌ·Ð : 2021-09-29
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
135 °æ±â Á¦59ȸ ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ¼¼¹Ì³ª : 2018-08-26 0 1,828 2018-07-28
134 ¼­¿ï Á¦8ȸ »ï¼º¼­¿ïº´¿ø ¼Ò¾Æû¼Ò³â¼¾ÅÍ ½ÉÆ÷Áö¾ö(ÁÖÁ¦: ÈçÈ÷ ¸¸³ª°Ô µÇ´Â ¼Ò¾Æû¼Ò³â Áúȯ) : 2018-08-26 0 700 2018-07-28
133 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø Á¦9ȸ ¿¬¼¼ÀÇ´ë ¼Ò¾Æ°úÇб³½Ç, ¼Ò¾Æ¾Ë·¹¸£±âÈ£Èí±âÁúȯ ¿¬¼ö°­Á : 2018-08-26 0 395 2018-07-28
132 ¼­¿ï 2018 ´ëÇѼö¸éÇÐȸ ¿öÅ©¼¥ : 2018-08-26 0 482 2018-07-28
131 °æºÏ ´ëÇѼҾưúÇÐȸ ¼Ò¾Æû¼Ò³â°ú ¿Ü·¡¿¡¼­ Àû¿ë °¡´ÉÇÑ ÀÓ»óÁö½Ä : 2018-08-26 0 652 2018-07-28
130 °æ³² ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ 2018 Post Graduate Asthma School (2ÀÏÂ÷) : 2018-08-26 0 1,080 2018-07-28
129 ¼­¿ï Á¦5ȸ ´ëÇÑ°³¿ø³»°úÀÇ»çȸ °¨¿°º´ ¹× ¹é½Å½ÉÆ÷Áö¿ò : 2018-08-26 0 527 2018-07-28
128 ¼­¿ï Á¦15Â÷ °æ±âµµÀÇ»çȸ Çмú´ëȸ : 2018-08-26 0 1,154 2018-07-28
127 °æ±â ÇѸ²´ëÇб³¼º½Éº´¿ø °³¿øÀǸ¦ À§ÇÑ °í/½½°üÀý Áúȯ : 2018-08-25 0 560 2018-07-28
126 ºÎ»ê ´ëÇÑÈäºÎ¿Ü°úÇÐȸ 2018 ECMO Symposium and Simulation Workshop : 2018-08-25 0 2,505 2018-07-28
125 ´ëÀü 2018³â ´ëÇÑÅëÁõÇÐȸ Áö¹æ¼øȸ ÃÊÀ½ÆÄ ¹× °æ¸·¿Ü³»½Ã°æWorkshop_ÃÊÀ½ÆÄ¿öÅ©¼ó : 2018-08-25 0 603 2018-07-28
124 ´ëÀü Ãæ³²´ëÇб³º´¿ø Ãæ³²´ëÇб³ ½Å°æ¿Ü°ú ȨĿ¹Ö ½ÉÆ÷Áö¿ò : 2018-08-25 0 900 2018-07-28
123 °æºÏ ´ëÇÑÁ¾¾ç³»°úÇÐȸ Best of ASCO 2018 in Korea : 2018-08-25 0 523 2018-07-28
122 ´ëÀü ´ëÇÑ°»³â±âÇÐȸ 2018 ÇÏ°è¿öÅ©¼¥ : 2018-08-25 0 384 2018-07-28
121 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ¼ö¸éÀÇÇÐ:´ÙÇÐÁ¦ Áø·áÀÇ ÀüÇü : 2018-08-25 0 797 2018-07-28
1401 | 1402 | 1403 | 1404 | 1405 | 1406 | 1407 | 1408 | 1409
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷